Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25395898
&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215
Oleanane triterpenoids in the prevention and therapy of breast cancer: current
evidence and future perspectives
#MMPMID25395898
Parikh NR
; Mandal A
; Bhatia D
; Siveen KS
; Sethi G
; Bishayee A
Phytochem Rev
2014[Dec]; 13
(4
): 793-810
PMID25395898
show ga
Breast cancer is one of the most frequently diagnosed cancers and major cause of
death in women in the world. Emerging evidence underscores the value of dietary
and non-dietary phytochemicals, including triterpenoids, in the prevention and
treatment of breast cancer. Oleanolic acid, an oleanane-type pentacyclic
triterpenoid, is present in a large number of dietary and medicinal plants.
Oleanolic acid and its derivatives exhibit several promising pharmacological
activities, including antioxidant, anti-inflammatory, hepatoprotective,
cardioprotective, antipruritic, spasmolytic, antiallergic, antimicrobial and
antiviral effects. Numerous studies indicate that oleanolic acid and other
oleanane triterpenoids modulate multiple intracellular signaling pathways and
exert chemopreventive and antitumor activities in various in vitro and in vivo
model systems. A series of novel synthetic oleanane triterpenoids have been
prepared by chemical modifications of oleanolic acid and some of these compounds
are considered to be the most potent anti-inflammatory and anticarcinogenic
triterpenoids. Accumulating studies provide extensive evidence that synthetic
oleanane derivatives inhibit proliferation and induce apoptosis of various cancer
cells in vitro and demonstrate cancer preventive or antitumor efficacy in animal
models of blood, breast, colon, connective tissue, liver, lung, pancreas,
prostate and skin cancer. This review critically examines the potential role of
oleanolic acid, oleanane triterpenoids and related synthetic compounds in the
chemoprevention and treatment of mammary neoplasia. Both in vitro and in vivo
studies on these agents and related molecular mechanisms are presented. Several
challenges and future directions of research to translate already available
impressive preclinical knowledge to clinical practice of breast cancer prevention
and therapy are also presented.